

Attorney Docket No.: 1256-R-00

FFW

In re Application of Michel Lazdunski et al.

Serial No.: 09/892,360

Filed: June 27, 2001

For: HUMAN TREK2, A STRETCH- AND ARACHICONIC ACID-SENSITIVE K⁺ CHANNEL ACTIVATED BY INHALATIONAL ANESTHETICS AND RILUZOLE

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment in the above-identified application.

Small entity status of this application under 37 CFR §1.9 and §1.27 has been established.

A verified statement to establish small entity status under 37 CFR §1.9 and §1.27 is enclosed.

No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)

(Col. 2) (Col. 3)

SMALL ENTITY

OTHER THAN
SMALL ENTITY

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PRE- VIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 5	-	** 27=	0
INDEP.	* 1	-	** 3=	0
Application Size Fee				
First Presentation of Multiple Dependent Claim				

RATE	ADD'L FEE
x 25 =	\$ 0
X 100 =	\$ 0
	\$ 0
+180=	\$ 0

OR

RATE	ADD'L FEE
x50 =	\$
x 200 =	\$
x250=	\$
+360=	\$

TOTAL ADDITIONAL FEE \$ 0 OR \$ _____

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 50-2719 in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.
- A check in the amount of \$ ____ is attached.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2719. A duplicate copy of this sheet is enclosed.
 - Any filing fees under 37 CFR §1.16 for the presentation of extra claims.
 - Any patent application processing fees under 37 CFR §1.17 with the exception of the Issue Fee which we intend to pay by check.

Respectfully submitted,



Paul Carango
Reg. No. 42,386
Attorney for Applicants

PC:SAN:vbm
(215) 656-3320



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645 CUSTOMER NO.: 035811
Serial No. : 09/892,360
Filed : June 27, 2001 Docket No.: 1256-R-00
Inventors : Michel Lazdunski
: Florian Lesage
: Georges Romey Confirmation No.: 2195
Title : HUMAN TREK2, A STRETCH- AND
: ARACHIDONIC ACID-SENSITIVE K⁺
: CHANNEL ACTIVATED BY INHALATIONAL
: ANESTHETICS AND RILUZOLE

Dated: January 13, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard
\$510 Check
Amendment Transmittal Letter, in duplicate
Amendment
Claim of Extension of Time, in duplicate


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Piper Rudnick LLP
Customer No. 035811

By: _____ *Paul Carango* _____

Date: 1/13/05



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	:	1645	CUSTOMER NO.: 035811
Serial No.	:	09/892,360	
Filed	:	June 27, 2001	
Inventors	:	Michel Lazdunski	Docket No.: 1256-R-00
	:	Florian Lesage	
	:	Georges Romey	Confirmation No.: 2195
Title	:	HUMAN TREK2, A STRETCH- AND ARACHIDONIC ACID-SENSITIVE K ⁺ CHANNEL ACTIVATED BY INHALATIONAL ANESTHETICS AND RILUZOLE	

Dated: January 13, 2005

AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Official Action dated July 19, 2004, please amend the Application as follows:

Amendments to the specification are on page 2 of this paper.

Amendments to the claims are on page 3 of this paper.

Remarks begin on page 4 of this paper.